Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference

Author's Avatar
May 11, 2022

STLA101 panel of 8 proprietary biomarkers can differentiate between the stages of esophageal cancer invasion and has previously demonstrated predictive power of detecting hallmarks of carcinogenesis in precancerous esophageal tissue